EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Direct Oral Anticoagulants Versus Low‐Molecular‐Weight Heparin for Treating Venous Thromboembolism in Patients With Gastrointestinal Cancer

Wei-Ting Chang, Mei-Chuan Lee, Hui-Wen Lin, Sheng-Hsiang Lin, Yi-Heng Li iD

Cancer Medicine · 2026

DOI: 10.1002/cam4.71838 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cancer Medicine, 2026. Verfasst von Wei-Ting Chang und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine and Doctoral Program of Clinical and Experimental Medicine, College of Medicine and Center of Excellence for Metabolic Associated …. Hauptthemen laut MEDLINE: Venous Thromboembolism, Heparin, Low-Molecular-Weight, Gastrointestinal Neoplasms, Anticoagulants. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chi Mei Medical Center, National Cheng Kung University Hospital, National Science and Technology Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Direct oral anticoagulants (DOACs) have demonstrated non‐inferiority to low‐molecular‐weight heparin (LMWH) for preventing recurrent venous thromboembolism (VTE) in cancer‐associated thrombosis. However, patients with gastrointestinal (GI) cancer receiving DOACs have reported increased major bleeding events. Hereby, we aim to compare the risks of recurrent thromboembolism and bleeding between those treated with DOACs and LMWH.

Methods

Using Taiwan's National Health Insurance Research Database, we retrospectively identified GI cancer patients with newly diagnosed VTE from 2011 to 2020. Outcomes were recurrent VTE and major bleeding. Covariate balancing was performed using inverse probability weighting, and Cox proportional hazards models compared risks, with a competing risk model for death. Follow‐up was 12 months.

Results

Among 1895 patients (1038 on DOACs, 857 on enoxaparin), recurrent VTE occurred in 20.71% of DOAC and 19.25% of enoxaparin patients. Competing risk analysis showed relatively higher recurrent VTE risk with DOACs (subdistribution HR, 1.27; 95% CI, 1.09–1.48; p < 0.01). Regarding composite bleeding risk, DOACs were similar compared with LMWH (subdistribution HR, 0.99; 95% CI, 0.68–1.45; p = 0.97). However, DOACs presented with an increased GI bleeding risk (subdistribution HR, 2.59; 95% CI, 1.48–4.54; p < 0.01) but a reduced intracranial hemorrhage risk (subdistribution HR, 0.35; 95% CI, 0.16–0.78; p = 0.01).

Conclusions

Compared with DOACs, LMWH expressed a lower risk of recurrent VTE in GI cancer patients. However, DOAC presented with a lower intracranial hemorrhage risk but a higher GI bleeding risk. Further research is needed to confirm these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Venous ThromboembolismHeparin, Low-Molecular-WeightGastrointestinal NeoplasmsAnticoagulantsFactor Xa InhibitorsHumansFemaleMaleMiddle AgedAgedRetrospective StudiesAdministration, OralTaiwanHemorrhageRecurrenceAged, 80 and overRisk Factors

Stichwörter der Autor:innen

gastrointestinal cancerlow molecular‐weight heparinoral anticoagulantsvenous thromboembolism

Substanzen

Heparin, Low-Molecular-WeightAnticoagulantsFactor Xa Inhibitors

Autor:innen und Institutionen

  • School of Medicine and Doctoral Program of Clinical and Experimental Medicine, College of Medicine and Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-sen University, Kaohsiung, Taiwa…
  • Department of Cardiology, Chi Mei Medical Center, Tainan, Taiwan.
  • School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan.
  • Department of Pharmacy, Chi Mei Medical Center, Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • Biostatistics Consulting Center, National Cheng Kung University, Tainan, Taiwan.
  • Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

ORCID-Profile: Yi-Heng Li

Förderung

  • Chi Mei Medical Center
  • National Cheng Kung University Hospital
  • National Science and Technology Council

Zitieren

APA

Chang, W. T., Lee, M. C., Lin, H. W., Lin, S. H., & Li, Y. H. (2026). Direct Oral Anticoagulants Versus Low‐Molecular‐Weight Heparin for Treating Venous Thromboembolism in Patients With Gastrointestinal Cancer. Cancer Medicine. https://doi.org/10.1002/cam4.71838

Vancouver

Chang WT, Lee MC, Lin HW, Lin SH, Li YH. Direct Oral Anticoagulants Versus Low‐Molecular‐Weight Heparin for Treating Venous Thromboembolism in Patients With Gastrointestinal Cancer. Cancer Medicine. 2026. doi:10.1002/cam4.71838

BibTeX
@article{Chang2026,
  author = {Chang, Wei-Ting and Lee, Mei-Chuan and Lin, Hui-Wen and Lin, Sheng-Hsiang and Li, Yi-Heng},
  title = {Direct Oral Anticoagulants Versus Low‐Molecular‐Weight Heparin for Treating Venous Thromboembolism in Patients With Gastrointestinal Cancer},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.71838}
}
Kostenlos starten →